Cognition Therapeutics (NASDAQ:CGTX) Rating Reiterated by Oppenheimer

Cognition Therapeutics (NASDAQ:CGTX)‘s stock had its “outperform” rating reissued by analysts at Oppenheimer in a research note issued to investors on Wednesday, Benzinga reports. They presently have a $9.00 price objective on the stock. Oppenheimer’s price objective would indicate a potential upside of 394.51% from the stock’s current price.

Cognition Therapeutics Price Performance

Shares of NASDAQ CGTX opened at $1.82 on Wednesday. The firm has a fifty day moving average price of $2.08 and a 200-day moving average price of $1.65. The stock has a market cap of $70.98 million, a PE ratio of -2.12 and a beta of 1.67. Cognition Therapeutics has a 1 year low of $0.90 and a 1 year high of $3.49.

Hedge Funds Weigh In On Cognition Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Pathstone Holdings LLC bought a new position in shares of Cognition Therapeutics during the fourth quarter worth $4,080,000. Vanguard Group Inc. boosted its position in shares of Cognition Therapeutics by 5.0% during the fourth quarter. Vanguard Group Inc. now owns 721,554 shares of the company’s stock worth $1,335,000 after acquiring an additional 34,658 shares during the last quarter. Worth Venture Partners LLC boosted its position in shares of Cognition Therapeutics by 1.4% during the second quarter. Worth Venture Partners LLC now owns 508,719 shares of the company’s stock worth $931,000 after acquiring an additional 7,000 shares during the last quarter. Kestra Advisory Services LLC boosted its position in shares of Cognition Therapeutics by 22.7% during the fourth quarter. Kestra Advisory Services LLC now owns 219,434 shares of the company’s stock worth $406,000 after acquiring an additional 40,650 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Cognition Therapeutics by 44.0% during the second quarter. Geode Capital Management LLC now owns 176,498 shares of the company’s stock worth $323,000 after acquiring an additional 53,900 shares during the last quarter. Institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex for the treatment of Alzheimer's disease.